Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04673942 · ClinicalTrials.gov registry record · Phase 2
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
A Phase 2 study of Cancer and Neoplasms, sponsored by EpicentRx.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 6
- Study locations
NCT04673942 is a Phase 2 study of Cancer and Neoplasms that is actively recruiting participants, run by EpicentRx. The registered enrollment target is 140 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT04673942, a Phase 2 study of Cancer and Neoplasms, is actively recruiting participants, sponsored by EpicentRx.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 6
- Study locations
Study Summary
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Conditions Studied
Interventions
- DRUG Checkpoint Inhibitor, Immune
- BIOLOGICAL AdAPT-001
Study Locations (6)
California
- City of Hope - Duarte
- California Cancer Associates for Research and Excellence, cCARE - San Marcos
- Providence Saint John's Health Center - Santa Monica
Texas
- Mary Crowley Cancer Research - Dallas
- MD Anderson Cancer Center - Houston
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04673942
The ClinicalTrials.gov registry entry for NCT04673942 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Checkpoint Inhibitor, Immune is the first listed.
NCT04673942 reports 6 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT04673942 about?
NCT04673942 is a clinical study titled "A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors". AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
What is the current status of trial NCT04673942?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2021-03-29. Estimated completion is 2027-03-01.
What conditions does trial NCT04673942 study?
This clinical trial studies the following conditions: Cancer, Neoplasms, Sarcoma, Solid Tumor, Adult, Chondrosarcoma.
What interventions are being tested in trial NCT04673942?
The interventions under investigation include: Checkpoint Inhibitor, Immune (DRUG), AdAPT-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04673942?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04673942 being conducted?
This trial has 6 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.